Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.

Autor: Selim R; Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, United States., Gordon SC; Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, United States.; School of Medicine, Wayne State University, Detroit, Michigan, United States., Zhou Y; Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, United States., Zhang T; Center on Aging & Health, Johns Hopkins University, Baltimore, Maryland, United States., Lu M; Center on Aging & Health, Johns Hopkins University, Baltimore, Maryland, United States., Daida YG; Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, United States., Boscarino JA; Biomedical Consulting Group LLC, Mahway, New Jersey, United States., Schmidt MA; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, United States., Trudeau S; Center on Aging & Health, Johns Hopkins University, Baltimore, Maryland, United States., Rupp LB; Department of Health Policy and Health Systems Research, Henry Ford Health, Detroit, Michigan, United States., Gonzalez HC; Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, United States.; School of Medicine, Wayne State University, Detroit, Michigan, United States.
Jazyk: angličtina
Zdroj: Journal of viral hepatitis [J Viral Hepat] 2023 Jun; Vol. 30 (6), pp. 544-550. Date of Electronic Publication: 2023 Mar 20.
DOI: 10.1111/jvh.13826
Abstrakt: Research suggests a possible link between chronic infection with hepatitis C virus (HCV) and the development of Parkinson's Disease (PD) and secondary Parkinsonism (PKM). We investigated the impact of antiviral treatment status (untreated, interferon [IFN] treated, direct-acting antiviral [DAA] treated) and outcome (treatment failure [TF] or sustained virological response [SVR]) on risk of PD/PKM among patients with HCV. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we applied a discrete time-to-event approach with PD/PKM as the outcome. We performed univariate followed by a multivariable modelling that used time-varying covariates, propensity scores to adjust for potential treatment selection bias and death as a competing risk. Among 17,199 confirmed HCV patients, we observed 54 incident cases of PD/PKM during a mean follow-up period of 17 years; 3753 patients died during follow-up. There was no significant association between treatment status/outcome and risk of PD/PKM. Type 2 diabetes tripled risk (hazard ratio [HR] 3.05; 95% CI 1.75-5.32; p < .0001) and presence of cirrhosis doubled risk of PD/PKM (HR 2.13, 95% CI 1.31-3.47). BMI >30 was associated with roughly 50% lower risk of PD/PKM than BMI <25 (HR 0.43; 0.22-0.84; p = .0138). After adjustment for treatment selection bias, we did not observe a significant association between HCV patients' antiviral treatment status/outcome on risk of PD/PKM. Several clinical risk factors-diabetes, cirrhosis and BMI-were associated with PD/PKM.
(© 2023 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje